GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eiger BioPharmaceuticals Inc (OTCPK:EIGRQ) » Definitions » Cyclically Adjusted Price-to-FCF

Eiger BioPharmaceuticals (Eiger BioPharmaceuticals) Cyclically Adjusted Price-to-FCF : (As of May. 16, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Eiger BioPharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Eiger BioPharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Eiger BioPharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eiger BioPharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Eiger BioPharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Eiger BioPharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Eiger BioPharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Eiger BioPharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eiger BioPharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eiger BioPharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Eiger BioPharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Eiger BioPharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Eiger BioPharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Eiger BioPharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-9.429/129.4194*129.4194
=-9.429

Current CPI (Dec. 2023) = 129.4194.

Eiger BioPharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -250.333 99.695 -324.972
201406 -160.000 100.560 -205.919
201409 -143.565 100.428 -185.009
201412 -193.750 99.070 -253.105
201503 -280.358 99.621 -364.218
201506 -238.736 100.684 -306.872
201509 -178.415 100.392 -230.003
201512 524.321 99.792 679.985
201603 -120.032 100.470 -154.617
201606 -67.076 101.688 -85.368
201609 -28.874 101.861 -36.686
201612 -39.939 101.863 -50.744
201703 -39.530 102.862 -49.736
201706 -32.032 103.349 -40.112
201709 -28.878 104.136 -35.889
201712 -31.783 104.011 -39.547
201803 -24.422 105.290 -30.019
201806 -19.627 106.317 -23.892
201809 -28.857 106.507 -35.065
201812 -21.226 105.998 -25.916
201903 -29.551 107.251 -35.659
201906 -19.472 108.070 -23.319
201909 -17.995 108.329 -21.498
201912 -18.906 108.420 -22.568
202003 -21.742 108.902 -25.838
202006 -18.702 108.767 -22.253
202009 -14.174 109.815 -16.704
202012 -14.386 109.897 -16.942
202103 -55.614 111.754 -64.405
202106 -18.090 114.631 -20.424
202109 -17.014 115.734 -19.026
202112 -14.901 117.630 -16.395
202203 -15.710 121.301 -16.761
202206 -15.153 125.017 -15.687
202209 -14.015 125.227 -14.484
202212 -15.134 125.222 -15.641
202303 -16.454 127.348 -16.722
202306 -14.930 128.729 -15.010
202309 -9.854 129.860 -9.821
202312 -9.429 129.419 -9.429

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eiger BioPharmaceuticals  (OTCPK:EIGRQ) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Eiger BioPharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Eiger BioPharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Eiger BioPharmaceuticals (Eiger BioPharmaceuticals) Business Description

Traded in Other Exchanges
Address
2155 Park Boulevard, Palo Alto, CA, USA, 94306
Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
Executives
Richard A Kayne 10 percent owner
Leen Kawas 10 percent owner 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Ingrid Choong officer: Chief Business Officer 24645 SUMMERHILL AVE, LOS ALTOS CA 94024
William G Kachioff officer: CFO 4060 PORTE DE PALMAS, SAN DIEGO CA 92122
James Vollins officer: General Counsel C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE SUITE 225, RALEIGH NC 27607
Mayer Eldon C. Iii officer: Ex VP & Chief Commerc. Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Lisa Kelly-croswell director C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Thomas John Dietz director C/O TRANSCEPT PHARMACEUTICAL, INC., 1003 W. CUTTING BLVD, STE 110, PT. RICHMOND CA 94804
Jeffrey S Glenn director 350 CAMBRIDGE AVENUE, SUITE 350, PALO ALTO CA 94306
David Apelian director C/O ACHILLION PHARMACEUTICALS, INC, 300 GEORGE STREET, NEW HAVEN CT 06511
Sriram Ryali officer: Chief Financial Officer C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Christine Murray director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Erik Atkisson officer: GC & Chief Compliance Officer C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Kim Sablich director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
David A Cory director, officer: President and CEO 350 CAMBRIDGE AVENUE, SUITE 350, PALO ALTO CA 94306